LegoChem Biosciences Signs ADC Technology Transfer Deal Worth 496.3 Billion KRW

UK ADC Therapeutics Developer Iksuda Therapeutics Advances ADC Cancer Treatment Development

[Asia Economy Reporter Park Hyungsoo] LegoChem Biosciences is transferring its antibody-drug conjugate (ADC) technology to a UK new drug development company.

On the 16th, according to related industries and LegoChem Bio, the ADC-based technology ConjuALL was licensed to UK-based ExsuDa Therapeutics.

ExsuDa is a company specializing in ADC therapeutic development. It will have exclusive rights for the global development and commercialization of ADC anticancer drugs targeting three targets using LegoChem Bio's ADC linker and toxin platform.

A LegoChem Bio official explained, "Like the technology transfer with Takeda last year, this is a non-exclusive global license agreement," and "for targets other than the three agreed with ExsuDa, additional technology transfer contracts can be made with other pharmaceutical companies."

LegoChem Bio can receive a total of 496.3 billion KRW, including upfront payments and milestone payments. Royalties are separate. If ExsuDa transfers the ADC to a third party during development, additional revenue will be distributed according to the agreed ratio.

ExsuDa was founded in 2012 by CEO David Simpson and other world-renowned ADC development experts. It also has a specialized ADC clinical development subsidiary in Boston, USA. Chief Scientific Officer (CSO) Robert Lutz participated in the clinical development of the blockbuster drug Kadcyla while working at ImmunoGen. He has experience in a total of eight ADC clinical developments.

CEO Simpson said, "We will leverage LegoChem Bio's excellent linker and next-generation PBD toxin along with our development capabilities to enter clinical trials as quickly as possible."

Kim Yongju, CEO of LegoChem Bio, introduced, "ExsuDa is a company with world-class ADC development capabilities," and added, "They will be able to bring LegoChem Bio's ADC technology to the clinical development stage faster than anyone else."

He also emphasized, "Through this contract, the ADC platform technology has received global recognition," and "Technology transfers for similar platform technologies and ADC pipeline materials under self-development will also accelerate."

LegoChem Bio has signed a total of six technology transfer contracts to date, including this one. The cumulative scale of technology transfers amounts to 1.7 trillion KRW. Aiming for more than three global technology transfers annually, LegoChem Bio is also pursuing additional technology transfers.

This content was produced with the assistance of AI translation services.